Mantle Cell Lymphoma · line 1 · Acalabrutinib + Rituximab (continuous BTKi + R)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-ACALABRUTINIB-RITUXIMAB |
| ID | IND-MCL-1L-BTKI-R |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-MCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB.
Used By
Algorithms
ALGO-MCL-1L- ALGO-MCL-1L